NASDAQ:SUPN   Supernus Pharmaceuticals, Inc
What used to be a resistance now a support.
Plus an inverse head & shoulders .
Plus positive news: “Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.'"
Going long anticipating 30’s where MA200 is and then maybe higher.
With tight stop-loss just behind the support.
Comment: Going to test 24.5 support
If it stands it, it might then go to the second target which is at around 50